Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience.

Apremilast, an oral selective phosphodiesterase 4 inhibitor, has been shown to be a safe and effective treatment for psoriasis and psoriatic arthritis (PsA). 1-3 Data from pivotal trials 4,5 and a recent retrospective evaluation in an Italian multicentric cohort of patients with PsA treated with apremilast 6 showed a retention rate of 72% after 6 months and approximately 50% after 1 year of follow-up.